BHCM
JBIO

Brevan Howard Capital Management’s Jade Biosciences JBIO Stock Holding History

Brevan Howard Capital Management’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$216K Buy
+9,704
New +$202K ﹤0.01% 1868

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Brevan Howard Capital Management's JBIO Position: Q2 2026 in Review

Brevan Howard Capital Management opened a new position in Jade Biosciences (JBIO) in Q2 2026: 9,704 shares worth $216K. The stake represents ﹤0.01% of the portfolio and ranks #1868 among its holdings.

154 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

  • Brevan Howard Capital Management held 9,704 shares of Jade Biosciences worth $216K as of Q2 2026.
  • Jade Biosciences was a new Brevan Howard Capital Management position in Q2 2026.
  • Jade Biosciences made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1868 holding.
  • 154 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.